Drug-assisted expectant care versus surgery for retained products of conception
A Prospective Multicenter Observational Real-world Study of Retained Products of Conception
This project tests whether trying drug-assisted expectant management and waiting for the right time for surgery in people with retained products of conception reduces intrauterine scarring and better preserves fertility compared with immediate curettage.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | The Third Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT07421895 on ClinicalTrials.gov |
What this trial studies
This is a prospective multicenter observational real-world study conducted at hospitals in Hunan, China. Patients with a clinical diagnosis of retained products of conception and an ultrasound lesion ≥0.5 cm will be followed after receiving either uterine curettage or drug-assisted expectant management until the clinician decides on surgery timing. The study will record rates of intrauterine adhesions and other fertility-related outcomes, as well as need for repeat procedures, infection, and bleeding. Patients with active bleeding requiring immediate surgery, obvious infection, or severe organ dysfunction are excluded and data will be used to compare real-world safety and effectiveness of the two approaches.
Who should consider this trial
Good fit: Ideal candidates are people with clinically diagnosed retained products of conception, an ultrasound lesion at least 0.5 cm in diameter, and no active bleeding, obvious infection, or severe organ dysfunction.
Not a fit: Patients with active heavy bleeding, clear infection, or severe organ dysfunction are unlikely to benefit from expectant management and will require immediate or alternative care.
Why it matters
Potential benefit: If successful, this approach could reduce intrauterine adhesions and help preserve future fertility by avoiding or better timing surgery.
How similar studies have performed: Some prior case series and observational reports suggest expectant or medical management can reduce immediate surgical interventions, but evidence that such approaches lower intrauterine adhesion rates is limited and mixed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:Clinical diagnosis of retained products of conception, and ultrasound indicated that the maximum diameter of the lesion ≥0.5cm. Exclusion Criteria:1) There is active bleeding requiring immediate surgical intervention;2) combined with obvious infection;3) Combined with severe organ dysfunction, including coagulation dysfunction.
Where this trial is running
Changsha, Hunan
- The Third Xiangya Hospital of Central South University — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Dabao MD
- Email: forxudabao@126.com
- Phone: 13017386201
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.